Bristol Myers Squibb Acquires 2seventy bio for $286M, Strengthening Cell Therapy Portfolio

Published on Spencer Knight via LinkedIn

Bristol Myers Squibb has acquired 2seventy bio in an all-cash deal worth $286 million, offering an 88% premium over 2seventy’s stock price. The companies previously co-developed Abecma, the first FDA-approved BCMA-directed CAR T therapy for multiple myeloma. This acquisition brings that partnership fully in-house and signals BMS’s deepening investment in cell therapy.

Spencer Knight sees this as part of a broader trend: pharma’s pivot toward CGT is gaining momentum, following a recent pullback from VCs. Strategic M&A like this shows confidence in long-term commercial viability and scientific value.

Read the full post on LinkedIn:

👉 Spencer Knight: BMS makes $286M Cell Therapy Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.